RT Journal Article SR Electronic T1 Effects of amyloid and APOE4 on medial temporal lobe subregions in cognitively unimpaired elderly JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.01.20.22269607 DO 10.1101/2022.01.20.22269607 A1 de Flores, Robin A1 Demeilliez-Servouin, Solène A1 Kuhn, Elizabeth A1 Chauveau, Léa A1 Landeau, Brigitte A1 Delcroix, Nicolas A1 Gonneaud, Julie A1 Chételat, Gaël YR 2022 UL http://medrxiv.org/content/early/2022/01/22/2022.01.20.22269607.abstract AB Medial temporal lobe (MTL) sub-structures are differentially affected in early Alzheimer’s disease (AD), with a specific involvement of the entorhinal cortex (ERC), the perirhinal cortex (PRC) and CA1. However, the impact of amyloid (Aβ) pathology and APOE ε4 on MTL subregional atrophy remains relatively unknown. Our aim was to uncover these effects to further our understanding of the mechanisms underlying MTL atrophy in a population at-risk for AD.We used baseline data from 130 unimpaired older adults (mean age: 68.9 ± 3.8 years) from the Age-Well randomized controlled trial for whom high-resolution structural MRI (T2-weighted; 0.4×0.4×2.5mm3), amyloid-PET (Florbetapir) and APOE genotype were available. Participants were dichotomized into amyloid positive (Aβ+, n=27) and negative (Aβ-, n=103), and APOE ε4 carrier (ε4+, n=35) and non-carriers (ε4-, n=95). Hippocampal subfield (CA1, CA2, CA3, dentate gyrus [DG], subiculum [SUB]) and extra-hippocampal region (ERC, Brodmann area [BA] 35 and 36, and parahippocampal cortex [PHC]) volumes were estimated using ASHS and normalized by total intracranial volume. For each subregion, group comparisons were performed (Aβ+ vs Aβ- and ε4+ vs ε4-) using ANCOVAs, including age, sex and education as covariates. Interactions with age (i.e., Aβ status * age and APOE ε4 status * age) were also investigated for each subregion.No significant differences were observed between Aβ+ and Aβ-, nor between ε4+ and ε4-. However, a significant Aβ status * age interaction were observed for CA1 (p<0.05), where volumes were negatively associated with age in the Aβ+ group only. In addition, significant APOE ε4 status * age interactions were found for CA1, SUB, ERC, DG and the whole hippocampus (p<0.05), where volumes were negatively associated with age in the ε4+ group only.Overall, our analyses showed that both Aβ and APOE ε4 status interact with age on CA1, which is known to be specifically atrophied in early AD. In addition, APOE ε4 status mediated the effects of age on other subregions (SUB, ERC, DG), suggesting a more important contribution of APOE ε4 than amyloid to MTL atrophy in cognitively unimpaired population. These results are particularly important to develop MRI-based biomarkers to detect early AD and further our understanding of the mechanisms underlying MTL atrophy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the European Union's Horizon 2020 Research and Innovation Program (Grant agreement no. 667696), Fondation Plan Alzheimer (Alzheimer Plan 2008-2012), Programme Hospitalier de Recherche Clinique (PHRCN 2011-A01493-38 and PHRCN 2012 12-006-0347), Agence Nationale de la Recherche (LONGVIE 2007), Institut National de la Sante et de la Recherche Medicale (INSERM), Region Normandie, Association France Alzheimer, Fondation Alzheimer, Fondation Recherche Alzheimer, Fondation d'Entreprise MMA des Entrepreneurs du Futur, and Fondation Entrepreneurs MMA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Protection des Personnes Nord-Ouest III of CHU Caen Normandie gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors